Selexis SA and TeneoBio, Inc. Team Up to Advance the Development of UniAbs Targeting Cancer

GENEVA & MENLO PARK, Calif.– (BUSINESS WIRE) — Selexis SA and TeneoBio, Inc. announced today that they have entered into a service agreement to advance the development of a new class of biologics, Human Heavy-Chain Antibodies (UniAbs®) targeting cancer.